卵巢透明细胞癌的临床特点及预后分析  

Clinical Characteristics and Prognostic Factors of Ovarian Clear Cell Carcinoma

作　　者：吴小肄[1] 徐洁[1] 徐丛剑[1] 卢颖[1] 

机构地区：[1]复旦大学附属妇产科医院,上海200011

出　　处：《中国临床医学》2011年第5期693-695,共3页Chinese Journal of Clinical Medicine

摘　　要：目的:探讨卵巢透明细胞癌的临床特点和影响其预后的因素。方法:回顾分析96例卵巢透明细胞癌患者的临床资料。结果:发病年龄较轻(55岁及以下者占80.2%),早期患者占大多数(71.9%)。国际妇产科协会(FIGO)分期I期者5年生存率为71.9%,II期者为50.0%,III期者为23.8%,IV期者为0.0%。合并子宫内膜异位症者高达50.0%。5年生存率与患者年龄、肿瘤病理学类型、化疗方案无关,而与肿瘤分期FIGO分期、术前糖链抗原125(CA125)值是否高于150 U/mL、肿瘤细胞减灭术满意程度、化疗方案的疗程是否足够有关。结论:早期卵巢透明细胞癌患者多见,易合并子宫内膜异位症,总体生存率低。早期发现疾病并进行理想的肿瘤细胞减灭术、术后足够疗程的化疗可望改善预后。Objective： To evaluate the clinical characteristics and prognostic factors in the patients with clear cell carcinoma of the ovary. Methods： The medical records of 96 patients with ovarian clear cell carcinoma treated in our hospital from January 1999 to September 2005 were reviewed and analyzed retrospectively, with a follow-up by telephone until April 2011. Results： Most patients were younger than 55 year-old （71.9%）. Majority of the group were in early stage. The five-year survival rate was 71.9%0 in stage I, 50.0% in stage II, 23.8% in stage III,0.0%in stage IV. Patients with pelvic endometriosis consist of 50% of all. Age of patients at diagnosis,histological type and differences of chemotherapy regimens were not prognostic factors. The International Federation of Gynecology and Obstetrics （FIGO） staging, carcinoma antigen 125 （CA 125） expression levels before our therapy, residual tumor diameter status and sufficient chemotherapeutic cycles were prognostic factors in the patients. Conclusions： The patients of ovarian clear cell carcinoma are often of early stage at diagnosis, with poor prognosis, apt to be combined with endometriosis. In order to improve the prognosis, it＇s necessary to diagnose the disease early and perform an optimal cytoreductive surgery as well as sufficient postoperative chemotherapy on the patients.

关 键 词：卵巢肿瘤 透明细胞癌 生存率 预后 

分 类 号：R737.31[医药卫生—肿瘤]